

Corning® Ultra-Low Attachment Surface Bibliography: Spheroid Culture of Tumor and Normal Cells



This document is a partial bibliography of some of the research using Corning® Ultra-Low Attachment Surface vessels in spheroid culture applications.

1. Balzer, E.M., R.A. Whipple, E.H. Cho, M.A. Matrone, and S.S. Martin. 2010. Antimitotic chemotherapeutics promote adhesive responses in detached and circulating tumor cells. *Breast Cancer Res Treat.* 121:65-78.
2. Botchkina, G.I., E.S. Zuniga, M. Das, Y. Wang, H. Wang, S. Zhu, A.G. Savitt, R.A. Rowehl, Y. Leyfman, J. Ju, K. Shroyer, and I. Ojima. 2010. New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells. *Mol Cancer.* 9:192.
3. Buchert, M., M. Papin, C. Bonnans, C. Darido, W.S. Raye, V. Garambois, A. Pelegrin, J.F. Bourgaux, J. Pannequin, D. Joubert, and F. Hollande. 2010. Symplekin promotes tumorigenicity by up-regulating claudin-2 expression. *Proc Natl Acad Sci U S A.* 107:2628-33.
4. Chiba, T., E. Suzuki, M. Negishi, A. Saraya, S. Miyagi, T. Konuma, S. Tanaka, M. Tada, F. Kanai, F. Imazeki, A. Iwama, and O. Yokosuka. 2011. 3-Deazaneplanocin A is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. *Int J Cancer.* doi: 10.1002/ijc.26264.
5. Cocciadiferro, L., V. Miceli, K.S. Kang, L.M. Polito, J.E. Trosko, and G. Carruba. 2009. Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines. *Ann N Y Acad Sci.* 1155:257-62.
6. Cohn, E., L. Ossowski, S. Bertran, C. Marzan, and E.F. Farias. 2010. RARalpha1 control of mammary gland ductal morphogenesis and wnt1-tumorigenesis. *Breast Cancer Res.* 12:R79.
7. Daurkin, I., E. Eruslanov, J. Vieweg, and S. Kusmartsev. 2010. Generation of antigen-presenting cells from tumor-infiltrated CD11b myeloid cells with DNA demethylating agent 5-aza-2'-deoxycytidine. *Cancer Immunol Immunother.* 59:697-706.
8. Deng, T., J.C. Liu, K.I. Pritchard, A. Eisen, and E. Zacksenhaus. 2009. Preferential killing of breast tumor initiating cells by N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine/tesmilifene. *Clin Cancer Res.* 15:119-30.
9. Engelmann, K., H. Shen, and O.J. Finn. 2008. MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. *Cancer Res.* 68:2419-26.
10. Eruslanov, E., I. Daurkin, J. Ortiz, J. Vieweg, and S. Kusmartsev. 2010. Pivotal Advance: Tumor-mediated induction of myeloid-derived suppressor cells and M2-polarized macrophages by altering intracellular PGE catabolism in myeloid cells. *J Leukoc Biol.* 88:839-48.
11. Eruslanov, E., I. Daurkin, J. Vieweg, Y. Daaka, and S. Kusmartsev. 2011. Aberrant PGE metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. *Int Immunopharmacol.* 11:848-55.
12. Eddy, A.P., S.E. Wright, K.A. Rewers-Felkins, M.A. Yenderrozos, B.A. Vorderstrasse, and J.S. Lindsey. 2009. Targeting migration inducing gene-7 inhibits carcinoma cell invasion, early primary tumor growth, and stimulates monocyte oncolytic activity. *Mol Cancer Ther.* 8:2412-23.
13. Fotovati, A., S. Abu-Ali, P.S. Wang, L.P. Deleyrolle, C. Lee, J. Triscott, J.Y. Chen, S. Franciosi, Y. Nakamura, Y. Sugita, T. Uchiyumi, M. Kuwano, B.R. Leavitt, S.K. Singh, A. Jury, C. Jones, H. Wakimoto, B.A. Reynolds, C.J. Pallen, and S.E. Dunn. 2011. YB-1 Bridges Neural Stem Cells and Brain Tumor-Initiating Cells via Its Roles in Differentiation and Cell Growth. *Cancer Res.* 71:5569-78.
14. Gallmeier, E., P.C. Hermann, M.T. Mueller, J.G. Machado, A. Ziesch, E.N. De Toni, A. Palagyi, C. Eisen, J.W. Ellwart, J. Rivera, B. Rubio-Viqueira, M. Hidalgo, F. Bunz, B. Goke, and C. Heeschen. 2011. Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction. *Stem Cells.* 29:418-29.
15. Gaur, P., E.L. Sceusi, S. Samuel, L. Xia, F. Fan, Y. Zhou, J. Lu, F. Tozzi, G. Lopez-Berestein, P. Vivas-Mejia, A. Rashid, J.B. Fleming, E.K. Abdalla, S.A. Curley, J.N. Vauthey, A.K. Sood, J.C. Yao, and L.M. Ellis. 2011. Identification of Cancer Stem Cells in Human Gastrointestinal Carcinoid and Neuroendocrine Tumors. *Gastroenterology.* 141:1728-37.
16. Ghosh, Z., M. Huang, S. Hu, K.D. Wilson, D. Dey, and J.C. Wu. 2011. Dissecting the oncogenic and tumorigenic potential of differentiated human induced pluripotent stem cells and human embryonic stem cells. *Cancer Res.* 71:5030-9.

17. Gondi, C.S., S.S. Lakka, D.H. Dinh, W.C. Olivero, M. Gujrati, and J.S. Rao. 2007. Intraperitoneal injection of a hairpin RNA-expressing plasmid targeting urokinase-type plasminogen activator (uPA) receptor and uPA retards angiogenesis and inhibits intracranial tumor growth in nude mice. *Clin Cancer Res.* 13:4051-60.
18. Hsiao, A.Y., Y.S. Torisawa, Y.C. Tung, S. Sud, R.S. Taichman, K.J. Pienta, and S. Takayama. 2009. Microfluidic system for formation of PC-3 prostate cancer co-culture spheroids. *Biomaterials.* 30:3020-7.
19. Iwamuro, M., T. Komaki, Y. Kubota, M. Seita, H. Kawamoto, T. Yuasa, J.M. Shahid, R.A. Hassan, W.A. Hassan, S. Nakaji, Y. Nishikawa, E. Kondo, K. Yamamoto, I.J. Fox, and N. Kobayashi. 2010. Hepatic differentiation of mouse iPS cells in vitro. *Cell Transplant.* 19:841-7.
20. Ji, Q., X. Hao, Y. Meng, M. Zhang, J. Desano, D. Fan, and L. Xu. 2008. Restoration of tumor suppressor miR-34 inhibits human p53-mutant gastric cancer tumorspheres. *BMC Cancer.* 8:266.
21. Ji, Q., X. Hao, M. Zhang, W. Tang, M. Yang, L. Li, D. Xiang, J.T. Desano, G.T. Bommer, D. Fan, E.R. Fearon, T.S. Lawrence, and L. Xu. 2009. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. *PLoS One.* 4:e6816.
22. Jiang, Z., T. Deng, R. Jones, H. Li, J.I. Herschkowitz, J.C. Liu, V.J. Weigman, M.S. Tsao, T.F. Lane, C.M. Perou, and E. Zacksenhaus. 2010. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. *J Clin Invest.* 120:3296-309.
23. Jinushi, M., S. Chiba, H. Yoshiyama, K. Masutomi, I. Kinoshita, H. Dosaka-Akita, H. Yagita, A. Takaoka, and H. Tahara. 2011. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. *Proc Natl Acad Sci U S A.* 108:12425-30.
24. Karimi-Busheri, F., A. Rasouli-Nia, J.R. Mackey, and M. Weinfeld. 2010. Senescence evasion by MCF-7 human breast tumor-initiating cells. *Breast Cancer Res.* 12:R31.
25. Khushal, P.R., B. Vadla, H. Krishnan, T.F. Ramlall, Y. Shen, H. Ichikawa, J.G. Geng, and G.S. Goldberg. 2010. Src activates Abl to augment Robo1 expression in order to promote tumor cell migration. *Oncotarget.* 1:198-209.
26. Kim, M.P., J.B. Fleming, H. Wang, J.L. Abbruzzese, W. Choi, S. Kopetz, D.J. McConkey, D.B. Evans, and G.E. Gallick. 2011. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. *PLoS One.* 6:e20636.
27. Kuwada, E., K. Kambara, T. Tadaki, and K. Noguchi. 2011. Insoluble fraction of tumor cell homogenate is a useful material for eliciting cytotoxic T lymphocytes: a unique method for protein solubilization. *Anticancer Res.* 31:881-91.
28. Li, X., Z. Jia, Y. Shen, H. Ichikawa, J. Jarvik, R.G. Nagele, and G.S. Goldberg. 2008. Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate. *Cancer Sci.* 99:1326-33.
29. Lin, T., L. Meng, Y. Li, and R.Y. Tsai. 2010. Tumor-initiating function of nucleostemin-enriched mammary tumor cells. *Cancer Res.* 70:9444-52.
30. Liu, J.C., T. Deng, R.S. Lehal, J. Kim, and E. Zacksenhaus. 2007. Identification of tumorsphere- and tumor-initiating cells in HER2/Neu-induced mammary tumors. *Cancer Res.* 67:8671-81.
31. Liu, L.N., R. Shivakumar, C. Allen, and J.C. Fratantoni. 2008. Delivery of whole tumor lysate into dendritic cells for cancer vaccination. *Methods Mol Biol.* 423:139-53.
32. Liu, X., N. Shin, H.K. Koblish, G. Yang, Q. Wang, K. Wang, L. Leffet, M.J. Hansbury, B. Thomas, M. Rupa, P. Waeltz, K.J. Bowman, P. Polam, R.B. Sparks, E.W. Yue, Y. Li, R. Wynn, J.S. Fridman, T.C. Burn, A.P. Combs, R.C. Newton, and P.A. Scherle. 2010. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. *Blood.* 115:3520-30.
33. Lui, V.W., D.M. Yau, E.Y. Wong, Y.K. Ng, C.P. Lau, Y. Ho, J.P. Chan, B. Hong, K. Ho, C.S. Cheung, C.M. Tsang, S.W. Tsao, and A.T. Chan. 2009. Cucurbitacin I elicits anoikis sensitization, inhibits cellular invasion and in vivo tumor formation ability of nasopharyngeal carcinoma cells. *Carcinogenesis.* 30:2085-94.
34. Luo, M., H. Fan, T. Nagy, H. Wei, C. Wang, S. Liu, M.S. Wicha, and J.L. Guan. 2009. Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. *Cancer Res.* 69:466-74.
35. Marian, C.O., W.E. Wright, and J.W. Shay. 2010. The effects of telomerase inhibition on prostate tumor-initiating cells. *Int J Cancer.* 127:321-31.
36. Marsden, C.G., M.J. Wright, R. Pochampally, and B.G. Rowan. 2009. Breast tumor-initiating cells isolated from patient core biopsies for study of hormone action. *Methods Mol Biol.* 590:363-75.

37. Matrone, M.A., R.A. Whipple, K. Thompson, E.H. Cho, M.I. Vitolo, E.M. Balzer, J.R. Yoon, O.B. Ioffe, K.C. Tuttle, M. Tan, and S.S. Martin. 2010. Metastatic breast tumors express increased tau, which promotes microtentacle formation and the reattachment of detached breast tumor cells. *Oncogene*. 29:3217-27.
38. Mawji, I.A., C.D. Simpson, R. Hurren, M. Gronda, M.A. Williams, J. Filmus, J. Jonkman, R.S. Da Costa, B.C. Wilson, M.P. Thomas, J.C. Reed, G.V. Glinisky, and A.D. Schimmer. 2007. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. *J Natl Cancer Inst*. 99:811-22.
39. Moran, T.P., J.E. Burgents, B. Long, I. Ferrer, E.M. Jaffee, R.M. Tisch, R.E. Johnston, and J.S. Serody. 2007. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neuro-overexpressing tumors in wild-type mice. *Vaccine*. 25:6604-12.
40. Mori, S., J.T. Chang, E.R. Andrechek, N. Matsumura, T. Baba, G. Yao, J.W. Kim, M. Gatzka, S. Murphy, and J.R. Nevins. 2009. Anchorage-independent cell growth signature identifies tumors with metastatic potential. *Oncogene*. 28:2796-805.
41. Pajic, M., A. Kersbergen, F. van Diepen, A. Pfauth, J. Jonkers, P. Borst, and S. Rottenberg. 2010. Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo. *Cell Cycle*. 9:3780-91.
42. Phipps, L.E., S. Hino, and R.J. Muschel. 2011. Targeting cell spreading: a method of sensitizing metastatic tumor cells to TRAIL-induced apoptosis. *Mol Cancer Res*. 9:249-58.
43. Rasheed, Z.A., J. Yang, Q. Wang, J. Kowalski, I. Freed, C. Murter, S.M. Hong, J.B. Koorstra, N.V. Rajeshkumar, X. He, M. Goggins, C. Iacobuzio-Donahue, D.M. Berman, D. Laheru, A. Jimeno, M. Hidalgo, A. Maitra, and W. Matsui. 2010. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. *J Natl Cancer Inst*. 102:340-51.
44. Robertson, F.M., M.A. Ogasawara, Z. Ye, K. Chu, R. Pickei, B.G. Debeb, W.A. Woodward, W.N. Hittelman, M. Cristofanilli, and S.H. Barsky. 2010. Imaging and analysis of 3D tumor spheroids enriched for a cancer stem cell phenotype. *J Biomol Screen*. 15:820-9.
45. Rolli, C.G., T. Seufferlein, R. Kemkemer, and J.P. Spatz. 2010. Impact of tumor cell cytoskeleton organization on invasiveness and migration: a microchannel-based approach. *PLoS One*. 5:e8726.
46. Simpson, C.D., I.A. Mawji, K. Anyiwe, M.A. Williams, X. Wang, A.L. Venugopal, M. Gronda, R. Hurren, S. Cheng, S. Serra, R. Beheshti Zavareh, A. Datti, J.L. Wrana, S. Ezzat, and A.D. Schimmer. 2009. Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. *Cancer Res*. 69:2739-47.
47. Song, L., S. Asgharzadeh, J. Salo, K. Engell, H.W. Wu, R. Sposto, T. Ara, A.M. Silverman, Y.A. DeClerck, R.C. Seeger, and L.S. Metelitsa. 2009. Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages. *J Clin Invest*. 119:1524-36.
48. Tang, B., N. Yoo, M. Vu, M. Mamura, J.S. Nam, A. Ooshima, Z. Du, P.Y. Desprez, M.R. Anver, A.M. Michalowska, J. Shih, W.T. Parks, and L.M. Wakefield. 2007. Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. *Cancer Res*. 67:8643-52.
49. Tang, Q.L., Z.Q. Zhao, J.C. Li, Y. Liang, J.Q. Yin, C.Y. Zou, X.B. Xie, Y.X. Zeng, J.N. Shen, T. Kang, and J. Wang. 2011. Salinomycin inhibits osteosarcoma by targeting its tumor stem cells. *Cancer Lett*. 311:113-21.
50. Thorner, A.R., J.S. Parker, K.A. Hoadley, and C.M. Perou. 2010. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. *PLoS One*. 5:e13073.
51. Tirino, V., V. Desiderio, F. Paino, A. De Rosa, F. Papaccio, F. Fazioli, G. Pirozzi, and G. Papaccio. 2011. Human primary bone sarcomas contain CD133+ cancer stem cells displaying high tumorigenicity in vivo. *Faseb J*. 25:2022-30.
52. Tsai, K.S., S.H. Yang, Y.P. Lei, C.C. Tsai, H.W. Chen, C.Y. Hsu, L.L. Chen, H.W. Wang, S.A. Miller, S.H. Chiou, M.C. Hung, and S.C. Hung. 2011. Mesenchymal stem cells promote formation of colorectal tumors in mice. *Gastroenterology*. 141:1046-56.
53. Vassilopoulos, A., R.H. Wang, C. Petrovas, D. Ambrozak, R. Koup, and C.X. Deng. 2008. Identification and characterization of cancer initiating cells from BRCA1 related mammary tumors using markers for normal mammary stem cells. *Int J Biol Sci*. 4:133-42.
54. Vazquez-Martin, A., C. Oliveras-Ferreras, S. Del Barco, B. Martin-Castillo, and J.A. Menendez. 2011. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. *Breast Cancer Res Treat*. 126:355-64.

55. Wang, X.Y., L.O. Penalva, H. Yuan, R.I. Linnoila, J. Lu, H. Okano, and R.I. Glazer. 2010. Musashi1 regulates breast tumor cell proliferation and is a prognostic indicator of poor survival. *Mol Cancer*. 9:221.
56. Watanabe, K., M.J. Meyer, L. Strizzi, J.M. Lee, M. Gonzales, C. Bianco, T. Nagaoka, S.S. Farid, N. Margaryan, M.J. Hendrix, B.K. Vonderhaar, and D.S. Salomon. 2010. Cripto-1 is a cell surface marker for a tumorigenic, undifferentiated subpopulation in human embryonal carcinoma cells. *Stem Cells*. 28:1303-14.
57. Workman, H.C., J.K. Miller, E.Q. Ingalla, R.P. Kaur, D.I. Yamamoto, L.A. Beckett, L.J. Young, R.D. Cardiff, A.D. Borowsky, K.L. Carraway, C. Sweeney, and K.L. Carraway, 3rd. 2009. The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. *Breast Cancer Res*. 11:R70.
58. Yamashita, T., J. Ji, A. Budhu, M. Forgues, W. Yang, H.Y. Wang, H. Jia, Q. Ye, L.X. Qin, E. Wauthier, L.M. Reid, H. Minato, M. Honda, S. Kaneko, Z.Y. Tang, and X.W. Wang. 2009. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. *Gastroenterology*. 136:1012-24.
59. Zhang, M., F. Behbod, R.L. Atkinson, M.D. Landis, F. Kittrell, D. Edwards, D. Medina, A. Tsimelzon, S. Hilsenbeck, J.E. Green, A.M. Michalowska, and J.M. Rosen. 2008. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. *Cancer Res*. 68:4674-82.
60. Zhang, S., C. Balch, M.W. Chan, H.C. Lai, D. Matei, J.M. Schilder, P.S. Yan, T.H. Huang, and K.P. Nephew. 2008. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. *Cancer Res*. 68:4311-20.
61. Zhang, Q., T. Yamaza, A.P. Kelly, S. Shi, S. Wang, J. Brown, L. Wang, S.W. French, and A.D. Le. 2009. Tumor-like stem cells derived from human keloid are governed by the inflammatory niche driven by IL-17/IL-6 axis. *PLoS One*. 4:e7798.
62. Zhu, M., R.E. Saxton, L. Ramos, D.D. Chang, B.Y. Karlan, J.C. Gasson, and D.J. Slamon. 2011. Neutralizing monoclonal antibody to periostin inhibits ovarian tumor growth and metastasis. *Mol Cancer Ther*. 10:1500-8.

For additional product or technical information, please visit www.corning.com/lifesciences or call 1.800.492.1110. Customers outside the United States, please call +1.978.442.2200 or contact your local Corning sales office listed below.

CORNING

Corning Incorporated *Life Sciences*

Tower 2, 4th Floor
900 Chelmsford St.
Lowell, MA 01851
t 800.492.1110
t 978.442.2200
f 978.442.2476

www.corning.com/lifesciences

Worldwide Support Offices

ASIA / PACIFIC

Australia/New Zealand
t 0402-794-347

China
t 86 21 2215 2888
f 86 21 6215 2988

India
t 91 124 4604000
f 91 124 4604099

Japan

t 81 3-3586 1996
f 81 3-3586 1291

Korea

t 82 2-796-9500
f 82 2-796-9300

Singapore

t 65 6733-6511
f 65 6861-2913

Taiwan

t 886 2-2716-0338
f 886 2-2516-7500

EUROPE

France

t 0800 916 882
f 0800 918 636

Germany

t 0800 101 1153
f 0800 101 2427

The Netherlands

t 31 20 655 79 28
f 31 20 659 76 73

United Kingdom

t 0800 376 8660
f 0800 279 1117

All Other European Countries

t 31 (0) 20 659 60 51
f 31 (0) 20 659 76 73

LATIN AMERICA

Brasil

t (55-11) 3089-7419
f (55-11) 3167-0700

Mexico

t (52-81) 8158-8400
f (52-81) 8313-8589